By Dr Wendy Winnall - PCFA Research TeamA recent prostate cancer study from Canada has received a lot of publicity. This study measured the risk of ...
Scientists Discover Breakthrough Method to Target Treatment-Resistant CancersCancer’s greatest trick is evolving to beat our ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...
CHAD Thompson grappled with a silent problem for 20 years – he couldn’t pee properly, and it was a constant source of anxiety ...
Everyday Health on MSN
High-Fat Cheese Could Be Good for Your Brain
Research counters the prevailing wisdom that all saturated fat is harmful by finding that moderate amounts of cheddar and other cheeses could boost brain health.
FOX 5 DC on MSN
New laws for DC, Maryland and Virginia on January 1, 2026
In 2026, residents in Virginia, Maryland, and Washington, D.C., will see significant changes as a range of new laws go into ...
Morning Overview on MSN
Night shifts may be quietly raising cancer risk, researchers suggest
Night work keeps hospitals open, factories humming and deliveries moving while most people sleep, but a growing body of ...
A major new pilot launching this month will allow health visiting teams to offer vaccinations directly to children during ...
The newly introduced double-crew ambulances feature advanced safety technology to protect both patients and paramedics. They ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of adults with a deleterious BRCA mutation (germline and/or ...
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback